

## MERCK SHARES

The Merck share price rose 2.7% during the third quarter, from EUR 59.99 on June 30 to EUR 61.62 on September 30. The share price high during the third quarter was EUR 72.28, recorded on September 10. The low price for the quarter was EUR 58.11 on July 5. Germany's DAX Index, of which Merck is a member, rose 4.4% during the third quarter and the Bloomberg Europe Pharmaceuticals Index rose 9.6%.

### Share data<sup>1</sup>

|                                                                  | 3 <sup>rd</sup> quarter<br>2010 | 2 <sup>nd</sup> quarter<br>2010 |
|------------------------------------------------------------------|---------------------------------|---------------------------------|
| Earnings per share after tax and non-controlling interest in EUR | 0.97                            | 0.84                            |
| Share price high in EUR                                          | (Sep. 10) 72.28                 | (April 27) 64.32                |
| Share price low in EUR                                           | (July 5) 58.11                  | (May 25) 57.65                  |
| Closing share price in EUR                                       | (Sep. 30) 61.62                 | (June 30) 59.99                 |
| Actual number of shares in millions                              | 64.6                            | 64.6                            |
| Theoretical number <sup>2</sup> of shares in millions            | 217.4                           | 217.4                           |
| Market capitalization <sup>3</sup> in EUR million                | 13,396                          | 13,041                          |

<sup>1</sup> Share-price relevant figures relate to the closing price in XETRA trading on the Frankfurt Stock Exchange.

<sup>2</sup> The calculation of the theoretical number of shares is based on the fact that the general partner's equity capital is not represented by shares. As the share capital of EUR 168.0 million was divided into 64.6 million shares, the corresponding calculation resulted in 152.8 million theoretical shares for the general partner's capital of EUR 397.2 million on the balance sheet date September 30, 2010.

<sup>3</sup> Based on the theoretical number of shares as of September 30, 2010.

### The performance of Merck shares vs. the DAX®/Bloomberg Europe Pharmaceuticals Index

in %

140

120

100

80

Oct. 2009      Dec.      March 2010      June      Sep.

■ Merck   ■ DAX®   ■ Bloomberg Europe Pharmaceuticals Index

